5-Androstenediol

From Wikipedia, the free encyclopedia

5-Androstenediol
Systematic (IUPAC) name
(3S,8R,9S,10R,13S,14S,17S)-10,13-Dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol
Identifiers
CAS number 521-17-5
ATC code  ?
PubChem  ?
Chemical data
Formula C19H30O2 
Mol. mass 290.44
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

5-Androstenediol (androst-5-ene-3beta,17beta-diol or 5-AED) is one of two androstenediols. Its potential use as a radiation countermeasure is being studied by Hollis-Eden Pharmaceuticals under the tradename Neumune for the treatment of acute radiation syndrome.[1]

The clinical trials on rhesus monkeys were successful. According to the Hollis-Eden report, only 12.5% of the 40 Neumune-treated animals died versus 32.5% in the placebo group.[2]

Hollis-Eden had applied for a contract from the US Government under the BioShield Request for Proposals (RFP) for radiation countermeasures. After being encouraged for 2.5 years that Neumune was in the competitive range, on March 9, 2007, the RFP was canceled by HHS. According to HHS, "the product was no longer in the competitive range".[3][4] No further explanation was given. As a result, Hollis-Eden has now withdrawn from the radiation countermeasure field.

[edit] References

  1. ^ Whitnall MH, Elliott TB, Harding RA, et al (2000). "Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice". Int. J. Immunopharmacol. 22 (1): 1–14. PMID 10684984. 
  2. ^ Hollis-Eden Pharmaceuticals Reports Publication of Results Demonstrating the Ability of NEUMUNE(R) to Increase Survival in a Primate Model of Lethal Radiation Injury, February 26, 2007.
  3. ^ Government Nukes Hollis-Eden's Radiation Drug, by Val Brickates Kennedy and Angela Moore, March 8, 2007
  4. ^ US cancels radiation contract with Hollis-Eden, March 9, 2007

[edit] External links


Languages